Cancer drug delays not due to PBAC processes

The Pharmaceutical Benefits Advisory Committee has spoken out against a perception that delays in access to the listing of cancer (and other) medicines are due to PBAC processes. PBAC informed the Senate Community Affairs References Committee Inquiry into the availability of new, innovative and specialist cancer drugs in Australia that in fact, delays are often